EMEligio Miccichè

Eligio Miccichè

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eligio Miccichè has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Percutaneous Rescue of Acute Left Ventricular Outflow Tract Obstruction After Mitral Valve‐In‐Valve Replacement

    by Andrea Mangiameli, Valentina Bernardini, Alessia Azzano, Eligio Miccichè, Elvis Brscic, Andrea Cascella, Rocco Mollace, Davide Cao

    Background: Left ventricular outflow tract obstruction (LVOTO) is a rare but potentially life‐threatening complication of transcatheter mitral valve replacement (TMVR). Mitral valve‐in‐valve procedures are generally associated with a lower risk of LVOTO because of the predictable geometry provided by the surgical bioprosthesis, yet severe obstruction may still occur and precipitate abrupt hemodynamic collapse. Case: A 79‐year‐old woman with a degenerated 27‐mm Carpentier‐Edwards Perimount mitral bioprosthesis presented with acute decompensated heart failure due to severe bioprosthetic mitral stenosis. Following multidisciplinary Heart Team evaluation, she was considered not a candidate for redo mitral valve surgery and underwent urgent transseptal valve‐in‐valve TMVR with a 26‐mm balloon‐expandable SAPIEN valve. Intervention: Immediately after valve deployment, severe LVOTO developed, with an invasive peak‐to‐peak LV‐aortic gradient of 120 mmHg. A mechanism‐guided percutaneous rescue strategy was undertaken. Correction of the structural component of obstruction reduced the gradient to 60 mmHg. Persistent obstruction suggested a significant dynamic contribution, prompting selective septal branch coil embolization, which further reduced the gradient to 20 mmHg and resulted in immediate hemodynamic stabilization. Conclusion: Severe LVOTO after valve‐in‐valve TMVR may reflect both structural and dynamic mechanisms. Persistence of significant obstruction after structural correction should prompt consideration of a dynamic component and may guide effective rescue therapy.

  • Open Access

    Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta‐Analysis

    by Angelo Oliva, Anna Maria Ioppolo, Mauro Chiarito, Alberto Cremonesi, Alessia Azzano, Eligio Miccichè, Andrea Mangiameli, Francesco Ariano, Giuseppe Ferrante, Bernhard Reimers, et al.

    Background: Percutaneous left atrial appendage closure (LAAC) has been suggested as an alternative to long‐term oral anticoagulation for nonvalvular atrial fibrillation, but comparative data remain scarce. We aimed to assess ischemic and bleeding outcomes of LAAC compared with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for the prevention of cardioembolic events in patients with atrial fibrillation. Methods and Results: Embase and MEDLINE were searched for randomized trials comparing LAAC, VKAs, and DOACs. The primary efficacy end point was any stroke or systemic embolism. Treatment effects were calculated from a network meta‐analysis and ranked according to the surface under the cumulative ranking curve. Seven trials and 73 199 patients were included. The risk of the primary end point was not statistically different between LAAC versus VKAs (odds ratio [OR], 0.92 [95% CI, 0.62–1.50]) and LAAC versus DOACs (OR, 1.11 [95% CI, 0.71–1.73]). LAAC and DOACs resulted in similar risk of major or minor (OR, 0.93 [95% CI, 0.61–1.42]) and major bleeding (OR, 0.92 [95% CI, 0.58–1.46]); however, after exclusion of procedural bleeding, bleeding risk was significantly lower in those undergoing LAAC. Both LAAC and DOACs reduced the risk of all‐cause death compared with VKAs (LAAC versus VKAs: OR, 0.70 [95% CI, 0.53–0.91]; DOACs versus VKAs: OR, 0.90 [95% CI, 0.85–0.95], respectively). DOACs ranked as the best treatment for stroke or systemic embolism prevention (66.9%) and LAAC for reducing major bleeding (63.9%) and death (96.4%). Conclusions: As a nonpharmacological alternative to oral anticoagulation for atrial fibrillation, LAAC showed similar efficacy and safety compared with VKAs or DOACs. Prospective confirmation from larger studies is warranted.